AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2024
Jan 4, 2024
29977_dirs_2024-01-04_fac23a39-f2c4-4e6f-831f-b79edad5ecd9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2024-01-02
Reporting Person: McCourt Marion (EVP Commercial)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-02 | Common Stock | S | 274 | $873.91 | Disposed | 15062 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 158 | Indirect |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 16, 2023.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3